ALT-B4 ‘IV Formulation → SC Formulation’, recognized for novelty and innovation by the U.S. 라이트닝 바카라 사이트 office
[by Ji, Yong Jun] Alteogen announced on July 17 that it had received notification from a local patent attorney regarding the registration of a U.S. material patent for ‘ALT-B4,’ a hyaluronidase developed using the company’s proprietary ‘Hybrozyme’ platform. The patent is scheduled to be formally registered with the United States Patent and Trademark Office (USPTO) on July 29, securing protection rights until early 2043.
The patent registration was finalized following the payment of the registration fee on July 5, after receiving a ‘Notice of Allowance (NOA)’ from the USPTO earlier this year. The process was completed upon fulfillment of follow-up procedures.
ALT-B4 is an enzyme that degrades the ‘hyaluronic acid layer’ in the extracellular matrix of subcutaneous tissue, thereby creating space for the delivery of therapeutic agents. Alteogen’s hyaluronidase enables the conversion of intravenously (IV) administered drugs into subcutaneous (SC) formulations. This allows pharmaceutical companies to reformulate existing blockbuster IV drugs into SC versions, potentially extending product patent lifespans and minimizing treatment-related side effects. According to the company, demand for Alteogen's hyaluronidase is increasing as it can facilitate drug life cycle management and new drug development.
Alteogen has licensed its Hybrozyme platform technology to six global pharmaceutical companies for the development of SC formulation treatments. With the registration of this 라이트닝 바카라 사이트, ALT-B4 is anticipated to pursue additional 라이트닝 바카라 사이트 applications and registrations as part of a strategic effort to offer robust intellectual property (IP) protection to current and prospective partners, thereby maintaining and extending market exclusivity in the United States.
“Given the significance of intellectual property rights in the biopharmaceutical industry, we conducted a comprehensive data review prior to registration, conducted a re-examination by the USPTO, and subsequently received the NOA, leading to this patent registration,” an Alteogen official said. “The timing of the patent registration was also strategically determined based on the date of the registration fee payment, taking various considerations into account.”
“Recognized by the USPTO for its novelty and innovativeness, the independently developed ALT-B4 will serve as a foundation for continued collaboration with various global pharmaceutical and biotechnology companies, with the goal of delivering improved treatment options to a broader patient population,” the official further remarked.